{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    9,
    14,
    22,
    33,
    34,
    36,
    38,
    39,
    40,
    45,
    46,
    47,
    50,
    51,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Dose Selection Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.4",
        "sectionTitle": "Rationale for dose selection",
        "description": "Reference to Section 3.9.1 for details on pharmacodynamics effects and dose selection."
      },
      {
        "id": "ref_2",
        "name": "E-PRO Exclusion Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.2",
        "sectionTitle": "Exclusion criteria",
        "description": "Reference to Section 5.1.11.5 for details regarding patient exclusion from ePRO assessments."
      },
      {
        "id": "ref_3",
        "name": "Incorrect Enrollment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.2",
        "sectionTitle": "Exclusion criteria",
        "description": "Reference to Section 3.4 for procedures for withdrawal of incorrectly enrolled patients."
      },
      {
        "id": "ref_4",
        "name": "Eligibility Determination Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.3",
        "sectionTitle": "Patient enrolment and randomisation",
        "description": "Reference to Section 3 for determining patient eligibility."
      },
      {
        "id": "ref_5",
        "name": "Stratification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2.1",
        "sectionTitle": "Visit 2, Randomisation (Day 0)",
        "description": "Reference to Section 3.5.1 for stratification and capping purposes."
      },
      {
        "id": "ref_6",
        "name": "Concomitant Medication Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2.2",
        "sectionTitle": "Visit 3 and Visit 4",
        "description": "Reference to Section 7.7 for changes in relevant concomitant medications."
      },
      {
        "id": "ref_7",
        "name": "Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2.6",
        "sectionTitle": "Premature treatment discontinuation visit (PTDV)",
        "description": "Reference to Section 3.9 for further details regarding discontinuations from IP."
      },
      {
        "id": "ref_8",
        "name": "Laboratory Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.1",
        "sectionTitle": "Endpoint reporting overview",
        "description": "Reference to Table 2 for laboratory assessments and timings."
      },
      {
        "id": "ref_9",
        "name": "NYHA Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.6",
        "sectionTitle": "New York Heart Association (NYHA) class",
        "description": "Reference to Appendix D for the definition of NYHA class."
      },
      {
        "id": "ref_10",
        "name": "PRO Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.11",
        "sectionTitle": "Patient reported outcomes (PROs)",
        "description": "Reference to Appendix E for PGIS, PGIC, KCCQ, and EQ-5D-5L questionnaires."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "NB: Patients who cannot complete the electronic patient reported outcome (ePRO) assessments can still participate in the study.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "3.2 Exclusion criteria",
        "pageNumber": 34
      },
      {
        "id": "annot_2",
        "text": "After stopping IP the investigator should ensure that the patient is treated according to standard clinical practice and ascertain there is a proper medical follow-up plan in place",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.2.7 Study Closure Visit (SCV)",
        "pageNumber": 52
      },
      {
        "id": "annot_3",
        "text": "Failure to meet the criteria for NT-proBNP is expected to be the main reason for screen failure in this study.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.1.1 Visit 1, Enrolment",
        "pageNumber": 46
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-10-26",
        "description": "Initial creation"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-10-26",
        "description": "Correcting typos, cross-references, adding Echocardiographic Sub-study, and expanding AE of interest for amputations.",
        "amendmentNumber": "Amendment 1"
      }
    ],
    "summary": {
      "referenceCount": 10,
      "annotationCount": 3,
      "versionCount": 2
    }
  }
}